Healthcare and Distribution Services - Audon Trap & Partners
Healthcare and Distribution Services - Audon Trap & Partners
Healthcare and Distribution Services - Audon Trap & Partners
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Biotechnology<br />
Best Medical International Fornix Biosciences Advisor to buyer<br />
Holl<strong>and</strong> Corporate Finance assisted Fornix BioSciences N.V. (www.fornix.nl), the<br />
BioPharmaceutical company listed on the Euronext Amsterdam stock exchange <strong>and</strong><br />
established in Lelystad on the acquisition of Best Medical International B.V.,<br />
established in Beuningen (Gelderl<strong>and</strong>).<br />
Best Medical International has developed a number of patented products that offer<br />
significant advantages with regard to urodynamic investigations performed in<br />
connection with urological disorders, such as diagnosing the nature <strong>and</strong> scale of<br />
incontinence. This extension of activities from Fornix is in pursuit of the desire to<br />
exp<strong>and</strong> the Fornix Theranostics division set up in August 2002.<br />
In addition to the activities noted above, Fornix BioSciences N.V. specialises in the<br />
production <strong>and</strong> sale of (mainly) anti-allergy pharmaceuticals, the trade in<br />
pharmaceuticals <strong>and</strong> research into new pharmaceuticals.<br />
Cytomics Rothschild & Cie Advisor to Cytomics<br />
Crossject is a global leader in the novel field of ubiquitine-proteasome pathway<br />
(Nobel prize 2004). Initially financed by the lifescience funds of Société Générale<br />
Asset Management AI, the company needed to secure a large source of equity<br />
investors to advance its products in clinical trial.<br />
Aelios Finance assisted the company in organizing a $14m financing transaction that<br />
was led by the lifescience fund of LCF Rothschild.<br />
M&A International Inc.<br />
member firm:<br />
Holl<strong>and</strong> Corporate Finance<br />
Aelios Finance<br />
Omrix Biopharmaceuticals Advisor to seller Capital Advice NV<br />
Omrix is a commercial-stage company that aims to develop <strong>and</strong> market innovative<br />
biosurgical <strong>and</strong> passive immunotherapy products, utilizing its proprietary protein<br />
purification technology <strong>and</strong> manufacturing know-how. The company’s biosurgical<br />
product line includes products <strong>and</strong> product c<strong>and</strong>idates that are used for the control<br />
of bleeding, or hemostasis, <strong>and</strong> other surgical applications.<br />
Omrix is currently partnered with Ethicon Inc., a Johnson & Johnson company, in the<br />
development of unique biosurgical devices which will meet critical unmet medical<br />
needs.<br />
Capital Advice led a fund raising round of USD 5mio. enabling the company to<br />
complete the final stages of its product registrations <strong>and</strong> to realize its aggressive<br />
marketing plans.<br />
13
Change language